PNC Financial Services Group’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,900
| Closed | -$244K | – | 5097 |
|
|
2025
Q2 | $244K | Buy |
1,900
+226
| +14% | +$23.5K | ﹤0.01% | 2085 |
|
|
2025
Q1 | $148K | Buy |
1,674
+24
| +1% | +$2.34K | ﹤0.01% | 2395 |
|
|
2024
Q4 | $144K | Buy |
1,650
+399
| +32% | +$36.5K | ﹤0.01% | 2440 |
|
|
2024
Q3 | $116K | Buy |
1,251
+115
| +10% | +$11.4K | ﹤0.01% | 2579 |
|
|
2024
Q2 | $122K | Sell |
1,136
-43
| -4% | -$4.3K | ﹤0.01% | 2501 |
|
|
2024
Q1 | $112K | Buy |
1,179
+363
| +44% | +$31.1K | ﹤0.01% | 2550 |
|
|
2023
Q4 | $75.3K | Sell |
816
-32
| -4% | -$2.07K | ﹤0.01% | 2763 |
|
|
2023
Q3 | $42.6K | Buy |
848
+329
| +63% | +$17.6K | ﹤0.01% | 3045 |
|
|
2023
Q2 | $32.8K | Buy |
519
+21
| +4% | +$1.14K | ﹤0.01% | 3290 |
|
|
2023
Q1 | $22.4K | Sell |
498
-175
| -26% | -$7.88K | ﹤0.01% | 3440 |
|
|
2022
Q4 | $29.5K | Sell |
673
-3,676
| -85% | -$176K | ﹤0.01% | 3275 |
|
|
2022
Q3 | $287K | Sell |
4,349
-1,945
| -31% | -$125K | ﹤0.01% | 1861 |
|
|
2022
Q2 | $318K | Buy |
6,294
+230
| +4% | +$13.5K | ﹤0.01% | 1831 |
|
|
2022
Q1 | $387K | Buy |
6,064
+23
| +0.4% | +$1.65K | ﹤0.01% | 1838 |
|
|
2021
Q4 | $647K | Sell |
6,041
-123
| -2% | -$12.9K | ﹤0.01% | 1537 |
|
|
2021
Q3 | $633K | Buy |
6,164
+100
| +2% | +$9.31K | ﹤0.01% | 1471 |
|
|
2021
Q2 | $534K | Sell |
6,064
-785
| -11% | -$71.9K | ﹤0.01% | 1555 |
|
|
2021
Q1 | $665K | Buy |
6,849
+491
| +8% | +$49K | ﹤0.01% | 1384 |
|
|
2020
Q4 | $713K | Sell |
6,358
-1,735
| -21% | -$183K | ﹤0.01% | 1284 |
|
|
2020
Q3 | $750K | Buy |
8,093
+832
| +11% | +$64.1K | ﹤0.01% | 1163 |
|
|
2020
Q2 | $566K | Sell |
7,261
-110
| -1% | -$7.44K | ﹤0.01% | 1303 |
|
|
2020
Q1 | $430K | Buy |
7,371
+2,211
| +43% | +$142K | ﹤0.01% | 1373 |
|
|
2019
Q4 | $414K | Sell |
5,160
-316
| -6% | -$23.7K | ﹤0.01% | 1588 |
|
|
2019
Q3 | $402K | Buy |
5,476
+500
| +10% | +$43.2K | ﹤0.01% | 1715 |
|
|
2019
Q2 | $468K | Buy |
4,976
+1,360
| +38% | +$112K | ﹤0.01% | 1659 |
|
|
2019
Q1 | $290K | Sell |
3,616
-639
| -15% | -$47.2K | ﹤0.01% | 1926 |
|
|
2018
Q4 | $229K | Buy |
4,255
+594
| +16% | +$36.1K | ﹤0.01% | 1969 |
|
|
2018
Q3 | $285K | Sell |
3,661
-12,576
| -77% | -$874K | ﹤0.01% | 1996 |
|
|
2018
Q2 | $1.03M | Buy |
16,237
+2,761
| +20% | +$220K | ﹤0.01% | 1309 |
|
|
2018
Q1 | $1.24M | Sell |
13,476
-379
| -3% | -$32.7K | ﹤0.01% | 1223 |
|
|
2017
Q4 | $1.05M | Buy |
+13,855
| New | +$975K | ﹤0.01% | 1314 |
|
Other funds holding BPMC
IA
HNB
PNC Financial Services Group's BPMC Position: Q3 2025 in Review
PNC Financial Services Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,900 shares — an estimated $244K sold.
PNC Financial Services Group first reported a position in BPMC in Q4 2017 and held it in 31 quarters. The position peaked at $1.24M in Q1 2018. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- PNC Financial Services Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- PNC Financial Services Group sold 1,900 Blueprint Medicines shares in Q3 2025, an estimated $244K.
- PNC Financial Services Group first reported a position in Blueprint Medicines in Q4 2017 and held it in 31 quarters.
- PNC Financial Services Group's Blueprint Medicines position peaked at $1.24M in Q1 2018.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.